Which has higher earnings & valuation, PHVS or SVA?

Sinovac Biotech has higher revenue and earnings than Pharvaris. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.05 N/A Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A

Is PHVS or SVA more profitable?

Sinovac Biotech's return on equity of 0.00% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -61.40% -56.00% Sinovac Biotech N/A N/A N/A

Does the media refer more to PHVS or SVA?

In the previous week, Pharvaris had 38 more articles in the media than Sinovac Biotech. MarketBeat recorded 41 mentions for Pharvaris and 3 mentions for Sinovac Biotech. Pharvaris' average media sentiment score of 0.56 beat Sinovac Biotech's score of 0.43 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 13 Very Positive mention(s) 7 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sinovac Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, BEAM or SVA?

Sinovac Biotech has higher revenue and earnings than Beam Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Beam Therapeutics $139.74M 17.73 -$79.99M -$0.86 N/A Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A

Does the media prefer BEAM or SVA?

In the previous week, Beam Therapeutics had 24 more articles in the media than Sinovac Biotech. MarketBeat recorded 27 mentions for Beam Therapeutics and 3 mentions for Sinovac Biotech. Beam Therapeutics' average media sentiment score of 0.48 beat Sinovac Biotech's score of 0.43 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 5 Very Positive mention(s) 4 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sinovac Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, GOSS or SVA?

Sinovac Biotech has higher revenue and earnings than Gossamer Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gossamer Bio $48.47M 0.65 -$170.37M -$0.70 N/A Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A

Is GOSS or SVA more profitable?

Sinovac Biotech has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Company Net Margins Return on Equity Return on Assets Gossamer Bio -235.00% N/A -112.04% Sinovac Biotech N/A N/A N/A

Does the media refer more to GOSS or SVA?

In the previous week, Gossamer Bio had 5 more articles in the media than Sinovac Biotech. MarketBeat recorded 8 mentions for Gossamer Bio and 3 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.43 beat Gossamer Bio's score of -0.13 indicating that Sinovac Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Sinovac Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, SVA or VERA?

Sinovac Biotech has higher revenue and earnings than Vera Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A Vera Therapeutics N/A N/A -$299.61M -$5.86 N/A

Is SVA or VERA more profitable?

Sinovac Biotech's return on equity of 0.00% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sinovac Biotech N/A N/A N/A Vera Therapeutics N/A -84.13% -66.79%

Does the media favor SVA or VERA?

In the previous week, Vera Therapeutics had 8 more articles in the media than Sinovac Biotech. MarketBeat recorded 11 mentions for Vera Therapeutics and 3 mentions for Sinovac Biotech. Vera Therapeutics' average media sentiment score of 1.35 beat Sinovac Biotech's score of 0.43 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sinovac Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vera Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, PGEN or SVA?

Sinovac Biotech has higher revenue and earnings than Precigen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precigen $9.68M 252.28 -$250.64M -$1.04 N/A Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A

Does the media prefer PGEN or SVA?

In the previous week, Sinovac Biotech had 1 more articles in the media than Precigen. MarketBeat recorded 3 mentions for Sinovac Biotech and 2 mentions for Precigen. Precigen's average media sentiment score of 1.54 beat Sinovac Biotech's score of 0.43 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Sinovac Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sinovac Biotech (SVA) Competitors

$6.47 0.00 (0.00%)

As of 09/11/2026

Compare

SVA vs. PHVS, BEAM, GOSS, VERA, and PGEN

Should you buy Sinovac Biotech stock or one of its competitors? Sinovac Biotech's main competitors and comparable companies include Pharvaris (PHVS), Beam Therapeutics (BEAM), Gossamer Bio (GOSS), Vera Therapeutics (VERA), and Precigen (PGEN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sinovac Biotech compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Sinovac Biotech (NASDAQ:SVA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Sinovac Biotech has higher revenue and earnings than Pharvaris.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A

In the previous week, Pharvaris had 38 more articles in the media than Sinovac Biotech. MarketBeat recorded 41 mentions for Pharvaris and 3 mentions for Sinovac Biotech. Pharvaris' average media sentiment score of 0.56 beat Sinovac Biotech's score of 0.43 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	13 Very Positive mention(s)	7 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sinovac Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pharvaris currently has a consensus price target of $59.50, suggesting a potential upside of 56.50%. Sinovac Biotech has a consensus price target of $1.00, suggesting a potential downside of 84.54%. Given Pharvaris' higher possible upside, research analysts plainly believe Pharvaris is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Pharvaris has a beta of -2.33, suggesting that its share price is 333% less volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market.

Sinovac Biotech's return on equity of 0.00% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-61.40%	-56.00%
Sinovac Biotech	N/A	N/A	N/A

Summary

Sinovac Biotech beats Pharvaris on 6 of the 10 factors compared between the two stocks.

How does Sinovac Biotech compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Sinovac Biotech (NASDAQ:SVA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Sinovac Biotech has higher revenue and earnings than Beam Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	17.73	-$79.99M	-$0.86	N/A
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A

In the previous week, Beam Therapeutics had 24 more articles in the media than Sinovac Biotech. MarketBeat recorded 27 mentions for Beam Therapeutics and 3 mentions for Sinovac Biotech. Beam Therapeutics' average media sentiment score of 0.48 beat Sinovac Biotech's score of 0.43 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	5 Very Positive mention(s)	4 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sinovac Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sinovac Biotech has a net margin of 0.00% compared to Beam Therapeutics' net margin of -54.75%. Sinovac Biotech's return on equity of 0.00% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Sinovac Biotech	N/A	N/A	N/A

99.7% of Beam Therapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 12.8% of Sinovac Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Beam Therapeutics has a beta of 2.22, meaning that its share price is 122% more volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

Beam Therapeutics currently has a consensus price target of $49.00, indicating a potential upside of 104.25%. Sinovac Biotech has a consensus price target of $1.00, indicating a potential downside of 84.54%. Given Beam Therapeutics' higher possible upside, equities analysts plainly believe Beam Therapeutics is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Beam Therapeutics and Sinovac Biotech tied by winning 7 of the 14 factors compared between the two stocks.

How does Sinovac Biotech compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Sinovac Biotech has higher revenue and earnings than Gossamer Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.65	-$170.37M	-$0.70	N/A
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A

Gossamer Bio presently has a consensus target price of $256.00, indicating a potential upside of 2,285.83%. Sinovac Biotech has a consensus target price of $1.00, indicating a potential downside of 84.54%. Given Gossamer Bio's higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Gossamer Bio had 5 more articles in the media than Sinovac Biotech. MarketBeat recorded 8 mentions for Gossamer Bio and 3 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.43 beat Gossamer Bio's score of -0.13 indicating that Sinovac Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sinovac Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gossamer Bio has a beta of 2, indicating that its stock price is 100% more volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

Sinovac Biotech has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
Sinovac Biotech	N/A	N/A	N/A

81.2% of Gossamer Bio shares are owned by institutional investors. 3.7% of Gossamer Bio shares are owned by insiders. Comparatively, 12.8% of Sinovac Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Sinovac Biotech beats Gossamer Bio on 8 of the 13 factors compared between the two stocks.

How does Sinovac Biotech compare to Vera Therapeutics?

Sinovac Biotech (NASDAQ:SVA) and Vera Therapeutics (NASDAQ:VERA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

99.2% of Vera Therapeutics shares are owned by institutional investors. 12.8% of Sinovac Biotech shares are owned by company insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Sinovac Biotech currently has a consensus target price of $1.00, indicating a potential downside of 84.54%. Vera Therapeutics has a consensus target price of $80.15, indicating a potential upside of 128.68%. Given Vera Therapeutics' higher possible upside, analysts plainly believe Vera Therapeutics is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Sinovac Biotech has higher revenue and earnings than Vera Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A

In the previous week, Vera Therapeutics had 8 more articles in the media than Sinovac Biotech. MarketBeat recorded 11 mentions for Vera Therapeutics and 3 mentions for Sinovac Biotech. Vera Therapeutics' average media sentiment score of 1.35 beat Sinovac Biotech's score of 0.43 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sinovac Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vera Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sinovac Biotech's return on equity of 0.00% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
Vera Therapeutics	N/A	-84.13%	-66.79%

Sinovac Biotech has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Summary

Vera Therapeutics beats Sinovac Biotech on 8 of the 13 factors compared between the two stocks.

How does Sinovac Biotech compare to Precigen?

Precigen (NASDAQ:PGEN) and Sinovac Biotech (NASDAQ:SVA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

In the previous week, Sinovac Biotech had 1 more articles in the media than Precigen. MarketBeat recorded 3 mentions for Sinovac Biotech and 2 mentions for Precigen. Precigen's average media sentiment score of 1.54 beat Sinovac Biotech's score of 0.43 indicating that Precigen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Sinovac Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sinovac Biotech has a net margin of 0.00% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Sinovac Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-183.98%	423.75%	84.39%
Sinovac Biotech	N/A	N/A	N/A

33.5% of Precigen shares are held by institutional investors. 41.4% of Precigen shares are held by insiders. Comparatively, 12.8% of Sinovac Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Sinovac Biotech has higher revenue and earnings than Precigen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	252.28	-$250.64M	-$1.04	N/A
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A

Precigen has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market.

Precigen currently has a consensus target price of $14.50, suggesting a potential upside of 111.68%. Sinovac Biotech has a consensus target price of $1.00, suggesting a potential downside of 84.54%. Given Precigen's higher possible upside, research analysts plainly believe Precigen is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Precigen beats Sinovac Biotech on 10 of the 15 factors compared between the two stocks.

Get Sinovac Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SVA vs. The Competition

Export

Metric	Sinovac Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$644.66M	$3.85B	$7.16B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.17%
P/E Ratio	N/A	14.18	274.94	25.36
Price / Sales	1.67	1,374.99	686.01	116.83
Price / Cash	11.89	106.50	76.65	51.52
Price / Book	0.07	15.12	10.33	6.20
Net Income	-$59.68M	-$22.86M	$3.50B	$358.50M
7 Day Performance	N/A	-4.34%	-3.32%	-2.35%
1 Month Performance	N/A	0.54%	-0.53%	-3.23%
1 Year Performance	N/A	40.74%	23.51%	8.79%

Sinovac Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SVA Sinovac Biotech	1.0884 of 5 stars	$6.47 flat	$1.00 -84.5%	N/A	$644.66M	$386.01M	N/A	3,008	News Coverage Analyst Forecast High Trading Volume
PHVS Pharvaris	3.7274 of 5 stars	$38.46 +2.5%	$59.50 +54.7%	+63.9%	$2.51B	N/A	N/A	30	Trending News Analyst Forecast Insider Trade High Trading Volume
BEAM Beam Therapeutics	2.3511 of 5 stars	$24.32 -0.2%	$49.00 +101.5%	+16.5%	$2.51B	$139.74M	N/A	510	Trending News Analyst Forecast Options Volume
GOSS Gossamer Bio	2.3418 of 5 stars	$10.65 -6.5%	$256.00 +2,303.8%	-96.1%	$2.49B	$48.47M	N/A	180	News Coverage Analyst Upgrade Gap Up
VERA Vera Therapeutics	3.0954 of 5 stars	$34.56 +2.9%	$80.15 +131.9%	+47.5%	$2.49B	N/A	N/A	40	News Coverage Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SVA) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sinovac Biotech (SVA) Competitors

SVA vs. PHVS, BEAM, GOSS, VERA, and PGEN

How does Sinovac Biotech compare to Pharvaris?

Summary

How does Sinovac Biotech compare to Beam Therapeutics?

Summary

How does Sinovac Biotech compare to Gossamer Bio?

Summary

How does Sinovac Biotech compare to Vera Therapeutics?

Summary

How does Sinovac Biotech compare to Precigen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA vs. The Competition

Sinovac Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sinovac Biotech (SVA) Competitors

SVA vs. PHVS, BEAM, GOSS, VERA, and PGEN

How does Sinovac Biotech compare to Pharvaris?

Which has higher earnings & valuation, PHVS or SVA?

Does the media refer more to PHVS or SVA?

Do analysts prefer PHVS or SVA?

Which has more volatility & risk, PHVS or SVA?

Is PHVS or SVA more profitable?

Summary

How does Sinovac Biotech compare to Beam Therapeutics?

Which has stronger earnings & valuation, BEAM or SVA?

Does the media prefer BEAM or SVA?

Is BEAM or SVA more profitable?

Do institutionals and insiders believe in BEAM or SVA?

Which has more risk & volatility, BEAM or SVA?

Do analysts prefer BEAM or SVA?

Summary

How does Sinovac Biotech compare to Gossamer Bio?

Which has stronger valuation and earnings, GOSS or SVA?

Do analysts rate GOSS or SVA?

Does the media refer more to GOSS or SVA?

Which has more risk & volatility, GOSS or SVA?

Is GOSS or SVA more profitable?

Do institutionals & insiders believe in GOSS or SVA?

Summary

How does Sinovac Biotech compare to Vera Therapeutics?

Do institutionals and insiders believe in SVA or VERA?

Do analysts recommend SVA or VERA?

Which has stronger earnings and valuation, SVA or VERA?

Does the media favor SVA or VERA?

Is SVA or VERA more profitable?

Which has more risk and volatility, SVA or VERA?

Summary

How does Sinovac Biotech compare to Precigen?

Does the media prefer PGEN or SVA?

Is PGEN or SVA more profitable?

Do insiders & institutionals have more ownership in PGEN or SVA?

Which has stronger valuation & earnings, PGEN or SVA?

Which has more risk & volatility, PGEN or SVA?

Do analysts recommend PGEN or SVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA vs. The Competition

Sinovac Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools